Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAM-II
- Development stage
- Preclinical
- Lead developer
- Epigen Biosciences
- Modality
- Small Molecules
01
Overview
PAM-II (also known as EPGN-1137) is a small-molecule positive allosteric modulator (PAM) of the alpha-7 nicotinic acetylcholine receptor (α7 nAChR). It is currently in preclinical development by Epigen Biosciences (in collaboration with the University of North Texas Health Science Center) for the treatment of stroke and traumatic brain injury (TBI). By positively modulating α7 nAChR, PAM-II enhances endogenous cholinergic pathways, which are widely expressed in neuronal and immune tissues, to promote neuroprotection and reduce neuroinflammation. This mechanism of action is also being explored for potential therapeutic extensions into cognitive and psychiatric disorders, such as dementias and schizophrenia.
- Other names
- Alpha7 nAChR PAMAlpha-7 nAChR PAMAlpha 7 nAChR PAMα7 nicotinic acetylcholine receptor positive allosteric modulatorα7 nicotinic receptor positive allosteric modulator
02
Targets
CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on PAM-II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAM-II.